Navigation Links
Vertos Medical, Inc. Appoints James M. Corbett Chief Executive Officer
Date:11/7/2008

Corbett and Daniel A. Pelak Join Board of Directors in Preparation for Launch of MILD(TM), an Innovative, Minimally Invasive Spinal Treatment

Procedure

SAN JOSE, Calif., Nov. 7 /PRNewswire/ -- Vertos Medical, Inc., a privately held medical device manufacturer focusing on a minimally invasive treatment for Lumbar Spinal Stenosis (LSS), today announced that the company has appointed James M. Corbett as its President and Chief Executive Officer and to its Board of Directors. In addition, the company announced it has expanded its Board to include Daniel A. Pelak. Corbett and Pelak bring decades of senior management experience in the development and commercialization of innovative medical devices. Vertos Medical, which has U.S. Food and Drug Administration (FDA) clearance for its MILD(TM) (Minimally Invasive Lumbar Decompression) technology, recently initiated an Institutional Review Board - controlled clinical trial called the Vertos MILD(TM) Preliminary Patient Evaluation Study.

The MILD(TM) procedure is a simple, percutaneous, fluoroscopically guided treatment for Lumbar Spinal Stenosis (LSS). MILD(TM) can be performed under local anesthesia and substantially reduces the tissue damage and removal associated with other minimally invasive or open surgeries. Recent clinical results in 32 patients(1) with moderate-to-severe LSS demonstrated improved mobility and decreased pain. To date, more than 80 patients have undergone the procedure without any adverse events.

In July 2008, Vertos completed a $12 million financing from leading venture capital firms CHL Medical Partners, Foundation Medical Partners, Aweida Ventures, and DFJ Mercury. With the addition of Mr. Corbett and Mr. Pelak, the Vertos Board expands to six members.

"We are delighted by the addition of these two seasoned executives to the Vertos Medical team. Jim has a proven track record in the medical device industry and brings demonstrated entrepreneurial leadership to Vertos as we prepare for the commercial rollout of the MILD(TM) procedure. In addition, we are pleased to have an executive with Dan's accomplishments and broad range of experience join our Board," said Myles Greenberg, M.D., Partner with CHL Medical Partners and Vertos Board member.

Mr. Corbett has more than 28 years of leadership experience in the medical device field. Most recently, he was Chief Executive Officer of ev3 Inc. (Nasdaq: EVVV), where he led the development of ev3's peripheral and neurovascular device business. Over the course of his career, Mr. Corbett has held the positions of Chief Executive Officer, Home Diagnostics Inc.; President, Boston Scientific International; and General Manager Baxter, Japan, as well as a number of executive roles in his 11 years at Baxter Healthcare.

Mr. Pelak has extensive medical device industry management experience, with a successful track record in growing young companies and productive corporate operating divisions. Until recently, he was the Chief Executive Officer at InnerPulse, a privately held, early-stage cardiac medical device company. Previously, he was the Chief Executive Officer of Closure Medical Corporation until its acquisition by Johnson & Johnson in 2005. He began his career at Medtronic, Inc., where he spent more than two decades and held the positions of Vice President of Cardiovascular Marketing, as well as Vice President and General Manager of three operating divisions.

About Vertos Medical, Inc.

Vertos is a San Jose, CA, based medical device company founded in 2005 which has recently begun commercializing an innovative, percutaneous treatment for lumbar spinal stenosis (LSS). LSS is a painful and debilitating condition diagnosed in more than 1.5 million people each year in the U.S. The Vertos MILD(TM) (Minimally Invasive Lumbar Decompression) procedure can be performed under local anesthesia and substantially reduces the tissue damage associated with other minimally invasive or open surgeries. Vertos has obtained FDA clearance for commercialization of the MILD(TM) devices in the U.S.

(1) Spine Technology Education Group, Innovative Techniques in Spine Surgery, June 18-21, 2008, Los Cabos, Mexico: 90% decrease in pain as measured by the Visual Analog Scale (VAS), as well as improved mobility, represented by a decrease in the Oswestry Disability Index (ODI) of 84%. No complications or adverse events reported. All patients discontinued the use of narcotics or pain medication at 6 weeks following the MILD procedure.


'/>"/>
SOURCE Vertos Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Vertos Medical Inc. Completes Series C Financing
2. Vertos Medical Inc. Presents Clinical Data of its MILD™ Procedure at the 5th Annual Innovative Techniques in Spine Surgery Conference in Los Cabos, Mexico
3. Interview with Dr. Elisabeth Hager, CEO of Balan Biomedical, Inc., to Air Nationally on Sky Radio
4. Nonin Medical, Inc. Showcases the First Pulse Oximeter Pre-Certified by the Continua Health Alliance
5. China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
6. China Sky One Medical, Inc. Acquires Drug to Treat Breast Lesions
7. China Sky One Medical, Inc. Receives Tax Refund
8. CSA Medical, Inc. Appoints President
9. Hoana Medical, Inc. Partners With Kahala Nui to Improve Patient Safety
10. China Sky One Medical, Inc. Signs Distribution Agreement with Harbin Baolong Pharmaceutical Company
11. Hamilton Medical, Inc. Welcomes New Vice President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... ... , ... People who have sensitive teeth are about as common as those ... Sadly, most dental hygiene products in the market contain chemical ingredients that only aggravate ... their daily oral care routine to keep their teeth white and healthy is a ...
(Date:1/13/2017)... ... January 13, 2017 , ... Friday, January 13 at 5 pm, America’s Incredible ... the size of the location to 90,000 square feet. , Included in the expansion ... takes customers on an educational tour of the historic route, with each hole in ...
(Date:1/13/2017)... ... 13, 2017 , ... MyGenetx, a molecular laboratory headquartered in middle Tennessee is ... Taylor Smith, RD, LD, will serve on the 2017 TBCC Board. , ... member and one year as Vice President. She will oversee the newly elected board ...
(Date:1/13/2017)... Boulder, CO (PRWEB) , ... January 13, 2017 , ... ... Congress, a growing alliance of deans of colleges and schools of education across the ... public schools. , In a Declaration of Principles released today, 175 deans sounded the ...
(Date:1/13/2017)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh, has published a new article that ... peace, health and eternal joy. Yisrayl says he has been accused of being the “prophet ... accusations and persecution are nothing new in his world and says it has always been ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... -- Wichita Laser Clinic at Healthy Life ... Wichita, Kansas featuring the Astanza Revolution ... rejuvenation, getting rid of unwanted tattoos, killing toenail fungus, ... "Since being in the aesthetics industry, I have ... for laser tattoo removal and other popular cosmetic ...
(Date:1/13/2017)... , Jan. 12, 2017   JDRF ... diabetes (T1D) research, is pleased to announce that ... the Centers for Medicare & Medicaid Services (CMS) ... by the FDA for use in making diabetes ... step toward making them eligible for coverage under ...
(Date:1/13/2017)... , Jan. 13, 2017 Over the last 10 years ... developing rapidly (6% – 10% yoy) and are expected to deliver remarkable ... the region, followed by Thailand , the ... , and Singapore .  A member of the G20 ... represents almost 40% of the SEA,s economic output and the largest pharma ...
Breaking Medicine Technology: